These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 20435479)
1. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Ling Y; Ye X; Ji H; Zhang Y; Lai Y; Peng S; Tian J Bioorg Med Chem; 2010 May; 18(10):3448-56. PubMed ID: 20435479 [TBL] [Abstract][Full Text] [Related]
2. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity. Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204 [TBL] [Abstract][Full Text] [Related]
3. Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells. Amos S; Redpath GT; Polar G; McPheson R; Schiff D; Hussaini IM Cell Death Differ; 2006 Apr; 13(4):642-51. PubMed ID: 16239932 [TBL] [Abstract][Full Text] [Related]
4. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents. Lai Y; Shen L; Zhang Z; Liu W; Zhang Y; Ji H; Tian J Bioorg Med Chem Lett; 2010 Nov; 20(22):6416-20. PubMed ID: 20932754 [TBL] [Abstract][Full Text] [Related]
6. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Rotblat B; Ehrlich M; Haklai R; Kloog Y Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment. Ling Y; Wang X; Zhu H; Wang Z; Xu C; Wang X; Chen L; Zhang W Arch Pharm (Weinheim); 2014 May; 347(5):327-33. PubMed ID: 24435839 [TBL] [Abstract][Full Text] [Related]
8. Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities. Ling Y; Wang Z; Wang X; Li X; Wang X; Zhang W; Dai H; Chen L; Zhang Y Chem Biol Drug Des; 2015 Feb; 85(2):145-52. PubMed ID: 25043275 [TBL] [Abstract][Full Text] [Related]
9. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents. Ling Y; Wang Z; Zhu H; Wang X; Zhang W; Wang X; Chen L; Huang Z; Zhang Y Bioorg Med Chem; 2014 Jan; 22(1):374-80. PubMed ID: 24300920 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety. Fang L; Zhang Y; Lehmann J; Wang Y; Ji H; Ding D Bioorg Med Chem Lett; 2007 Feb; 17(4):1062-6. PubMed ID: 17129724 [TBL] [Abstract][Full Text] [Related]
12. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500 [TBL] [Abstract][Full Text] [Related]
14. Getting at MYC through RAS. Bachireddy P; Bendapudi PK; Felsher DW Clin Cancer Res; 2005 Jun; 11(12):4278-81. PubMed ID: 15958607 [No Abstract] [Full Text] [Related]
15. Design, synthesis and anti-tumor evaluation of novel steroidal glycoconjugate with furoxan derivatives. Li H; Wang K; Wan Q; Chen Y Steroids; 2019 Jan; 141():81-95. PubMed ID: 30521816 [TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. Rao YK; Fang SH; Tzeng YM Bioorg Med Chem; 2009 Dec; 17(23):7909-14. PubMed ID: 19875299 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles. Kumar D; Patel G; Johnson EO; Shah K Bioorg Med Chem Lett; 2009 May; 19(10):2739-41. PubMed ID: 19376704 [TBL] [Abstract][Full Text] [Related]
20. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. Mor A; Kloog Y; Keren G; George J Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]